Trials / Completed
CompletedNCT03458117
T-VEC in Non-melanoma Skin Cancer
A Phase I, Open Label, Single Arm, Single Centre Study to Evaluate Mechanism of Action of Talimogene Laherparepvec (T-VEC) in Locally Advanced Non-melanoma Skin Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- University of Zurich · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the mechanism of Action of talimogene laherparepvec (T-VEC) in patients with locally advanced non-melanoma skin cancer.
Detailed description
This study evaluates the administration of T-VEC in non-melanoma skin cancer. The aim is to evaluate the effectiveness, safety and tolerability of T-VEC in patients with non-melanoma skin cancer through determination of local immune effects after repeated T-VEC injections.
Conditions
- Non-melanoma Skin Cancer
- Basal Cell Carcinoma
- Squamous Cell Carcinoma
- Cutaneous Lymphoma
- Merkel Cell Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Talimogene Laherparepvec (T-VEC) | a modified herpes simplex virus-1 (HSV-1) containing the gene coding for human granulocyte macrophage colony-stimulating factor (GM-CSF) |
Timeline
- Start date
- 2018-04-19
- Primary completion
- 2022-02-04
- Completion
- 2022-03-15
- First posted
- 2018-03-08
- Last updated
- 2022-03-18
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT03458117. Inclusion in this directory is not an endorsement.